The Drug Discovery and Delivery (DDD) Core facility represents one of the multi-user core facilities of the Center for Cancer Research in the RCMI program at Xavier University of Louisiana (Xavier). The DDD Core is established based on the existing strengths and needs of faculty actively pursuing research in drug development at Xavier. The long-term goal of the DDD Core facility is to further strengthen and enhance the capability of Xavier faculty to conduct competitive research in drug development. To accomplish this, we have assembled a group of experienced researchers with expertise in molecular modeling and drug design, synthesis, testing, and delivery to support the multidisciplinary research projects of faculty in Pharmacy, Chemistry, and Biology at Xavier. The DDD Core researchers will foster collaborative projects not only with faculty on campus, but also at other RCMI and research intensive Universities. The DDD Core has a strong foundation in drug design, synthesis and delivery, and will play a key role in translating basic scientific discoveries into potential therapeutics for human diseases, such as cancer. The establishment of the DDD Core will strengthen not only the drug discovery projects of the faculty, but also the institutional commitment to eliminate health disparities by supporting the development of potential therapeutics for cancer, a disease which disproportionately affects the minority population.

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12MD007595-10
Application #
9460927
Study Section
Special Emphasis Panel (ZMD1)
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
10
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Xavier University of Louisiana
Department
Type
DUNS #
020857876
City
New Orleans
State
LA
Country
United States
Zip Code
70125
Komati, Rajesh; Mitchell, Carl A; LeBeaud, Anastasia et al. (2018) Tenacic Acids: A New Class of Tenacious Binders to Metal Oxide Surfaces. Chemistry 24:14824-14829
Yao, Xin; Gray, Selena; Pham, Tri et al. (2018) Downregulation of Bit1 expression promotes growth, anoikis resistance, and transformation of immortalized human bronchial epithelial cells via Erk activation-dependent suppression of E-cadherin. Biochem Biophys Res Commun 495:1240-1248
Toro, Tasha B; Edenfield, Samantha A; Hylton, Brandon J et al. (2018) Chelatable trace zinc causes low, irreproducible KDAC8 activity. Anal Biochem 540-541:9-14
Echeverri, Margarita; Anderson, David; Nápoles, Anna María et al. (2018) Cancer Health Literacy and Willingness to Participate in Cancer Research and Donate Bio-Specimens. Int J Environ Res Public Health 15:
Schexnayder, Chandler; Broussard, Kiera; Onuaguluchi, Demitrius et al. (2018) Metformin Inhibits Migration and Invasion by Suppressing ROS Production and COX2 Expression in MDA-MB-231 Breast Cancer Cells. Int J Mol Sci 19:
Ponnapakkam, Tulasi; Saulsberry, Tyjah; Hill, Tarius et al. (2018) Inhibition of breast tumor growth in mice after treatment with ceramide analog 315. Anticancer Drugs 29:898-903
Al-Horani, Rami A; Afosah, Daniel K (2018) Recent advances in the discovery and development of factor XI/XIa inhibitors. Med Res Rev 38:1974-2023
Mei, Suyu; Flemington, Erik K; Zhang, Kun (2018) Transferring knowledge of bacterial protein interaction networks to predict pathogen targeted human genes and immune signaling pathways: a case study on M. tuberculosis. BMC Genomics 19:505
Aqeel, Salem M; Huang, Zhongyuan; Walton, Jonathan et al. (2018) Polyvinylidene Fluoride (PVDF)/Polyacrylonitrile (PAN)/Carbon Nanotube Nanocomposites for Energy Storage and Conversion. Adv Compos Hybrid Mater 1:185-192
Zheng, Shilong; Guo, Shanchun; Zhong, Qiu et al. (2018) Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors. ACS Med Chem Lett 9:149-154

Showing the most recent 10 out of 244 publications